Vericel (VCEL) Cost of Revenue (2011 - 2026)
Vericel (VCEL) posted Cost of Revenue of $21.1 million for Q2 2026, up 9.9% sequentially from $19.2 million in Q1 2026, and up 26.63% YoY from $16.6 million in Q2 2025.
Analysis
Vericel (VCEL) Cost of Revenue (2011 - 2026) Analysis & Trends
Vericel has reported Cost of Revenue for 16 years, with the latest figure at $21.1 million in Q2 2026.
- Quarterly Cost of Revenue rose 26.63% year-over-year to $21.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.9 million (up 17.92% YoY) and the FY2025 annual result came in at $70.7 million, up 8.51% from the prior year.
- Cost of Revenue rose to $21.1 million in Q2 2026 per VCEL's latest filing, from $19.2 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $21.1 million in Q2 2026 and troughed at $12.6 million in Q1 2022.
- A 5-year average of $16.3 million and a median of $16.2 million in 2024 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2024 and 2026: Cost of Revenue advanced 0.5% in 2024, then climbed 26.63% in 2026.
- Over 5 years, Cost of Revenue stood at $14.4 million in 2022, then increased by 14.15% to $16.5 million in 2023, then advanced by 2.35% to $16.9 million in 2024, then increased by 17.26% to $19.8 million in 2025, then advanced by 6.39% to $21.1 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $21.1 million, $19.2 million, and $19.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 21.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.06 Mn |
| Mar 31, 2026 | 19.16 Mn |
| Dec 31, 2025 | 19.79 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Jun 30, 2025 | 16.63 Mn |
| Mar 31, 2025 | 16.33 Mn |
| Dec 31, 2024 | 16.88 Mn |
| Sep 30, 2024 | 16.25 Mn |
| Jun 30, 2024 | 16.06 Mn |
| Mar 31, 2024 | 15.93 Mn |
| Dec 31, 2023 | 16.49 Mn |
| Sep 30, 2023 | 14.97 Mn |
| Jun 30, 2023 | 15.98 Mn |
| Mar 31, 2023 | 14.50 Mn |
| Dec 31, 2022 | 14.45 Mn |
| Sep 30, 2022 | 13.32 Mn |
| Jun 30, 2022 | 14.19 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Dec 31, 2021 | 13.56 Mn |
| Sep 30, 2021 | 12.41 Mn |